Growth differentiation factor 15 plasma levels and outcome after ischemic stroke
Standard
Growth differentiation factor 15 plasma levels and outcome after ischemic stroke. / Worthmann, Hans; Kempf, Tibor; Widera, Christian; Tryc, Anita B; Goldbecker, Annemarie; Ma, Yue T; Deb-Chatterji, Milani; Tountopoulou, Argyro; Lambrecht, Jürgen; Heeren, Meike; Lichtinghagen, Ralf; Wollert, Kai C; Weissenborn, Karin.
In: CEREBROVASC DIS, Vol. 32, No. 1, 2011, p. 72-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Growth differentiation factor 15 plasma levels and outcome after ischemic stroke
AU - Worthmann, Hans
AU - Kempf, Tibor
AU - Widera, Christian
AU - Tryc, Anita B
AU - Goldbecker, Annemarie
AU - Ma, Yue T
AU - Deb-Chatterji, Milani
AU - Tountopoulou, Argyro
AU - Lambrecht, Jürgen
AU - Heeren, Meike
AU - Lichtinghagen, Ralf
AU - Wollert, Kai C
AU - Weissenborn, Karin
N1 - Copyright © 2011 S. Karger AG, Basel.
PY - 2011
Y1 - 2011
N2 - BACKGROUND: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that is induced after experimental brain injury. We hypothesized that the circulating levels of GDF-15 are increased and associated with neurological outcome in patients with ischemic stroke.METHODS: Serial blood samples were obtained between 6 h and 7 days after symptom onset in 57 consecutive patients with acute ischemic stroke (n = 51) or transient ischemic attack (n = 6). GDF-15 was measured by immunoradiometric assay. Neurological outcome using the modified Rankin Scale (mRS) at 7 and 90 days was classified as favorable (mRS 0 or 1) or unfavorable (mRS >1).RESULTS: Six hours after symptom onset, GDF-15 levels were abnormally high (>1,200 ng/l) in 68% of the patients. They declined by 8% over the course of 7 days (p < 0.001). GDF-15 levels were correlated with the circulating levels of the inflammatory marker interleukin-6 and the glial protein S100 calcium binding protein B, and with carotid intima-media thickness. Ischemic stroke patients with an mRS score >1 at 7 or 90 days had higher circulating levels of GDF-15 at all preceding sampling time points compared to patients with an mRS score of 0 or 1 (p ≤ 0.002). Similarly, in a logistic regression analysis, GDF-15 levels measured between 6 h and 7 days after symptom onset were associated with mRS at 7 and 90 days.CONCLUSIONS: These data show for the first time that the circulating levels of GDF-15 are elevated and associated with neurological outcome in patients with ischemic stroke.
AB - BACKGROUND: Growth differentiation factor 15 (GDF-15) is a stress-responsive cytokine that is induced after experimental brain injury. We hypothesized that the circulating levels of GDF-15 are increased and associated with neurological outcome in patients with ischemic stroke.METHODS: Serial blood samples were obtained between 6 h and 7 days after symptom onset in 57 consecutive patients with acute ischemic stroke (n = 51) or transient ischemic attack (n = 6). GDF-15 was measured by immunoradiometric assay. Neurological outcome using the modified Rankin Scale (mRS) at 7 and 90 days was classified as favorable (mRS 0 or 1) or unfavorable (mRS >1).RESULTS: Six hours after symptom onset, GDF-15 levels were abnormally high (>1,200 ng/l) in 68% of the patients. They declined by 8% over the course of 7 days (p < 0.001). GDF-15 levels were correlated with the circulating levels of the inflammatory marker interleukin-6 and the glial protein S100 calcium binding protein B, and with carotid intima-media thickness. Ischemic stroke patients with an mRS score >1 at 7 or 90 days had higher circulating levels of GDF-15 at all preceding sampling time points compared to patients with an mRS score of 0 or 1 (p ≤ 0.002). Similarly, in a logistic regression analysis, GDF-15 levels measured between 6 h and 7 days after symptom onset were associated with mRS at 7 and 90 days.CONCLUSIONS: These data show for the first time that the circulating levels of GDF-15 are elevated and associated with neurological outcome in patients with ischemic stroke.
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers
KW - Female
KW - Growth Differentiation Factor 15
KW - Humans
KW - Ischemic Attack, Transient
KW - Male
KW - Nerve Growth Factors
KW - Neurologic Examination
KW - Predictive Value of Tests
KW - Prognosis
KW - Regression Analysis
KW - Retrospective Studies
KW - S100 Calcium Binding Protein beta Subunit
KW - S100 Proteins
KW - Sensitivity and Specificity
KW - Stroke
KW - Time Factors
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1159/000328233
DO - 10.1159/000328233
M3 - SCORING: Journal article
C2 - 21613788
VL - 32
SP - 72
EP - 78
JO - CEREBROVASC DIS
JF - CEREBROVASC DIS
SN - 1015-9770
IS - 1
ER -